



12 August 2015

EMPLOYEE SHARE PLAN VESTING CONDITIONS MET

SYDNEY, 12 August 2015: The Board of Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer's disease and other major age-related neurodegenerative disorders, wishes to advise that the following vesting condition has been met on Employee Share Plan shares issued to Dr Jason Loveridge:

Tranche	Number of Shares	Vesting Condition
Class B	3,000,000	On successful completion of phase 1 multiple ascending dose (MAD) study.

ENDS

Actinogen Medical

Dr Bill Ketelbey

Managing Director

P: +61 2 9251 5620

E: bill.ketelbey@actinogen.com.au

About Actinogen Medical

Actinogen Medical is focused on the treatment of Alzheimer's disease and mild cognitive impairment, a transitional stage of cognitive impairment between normal aging and the more serious condition of Alzheimer's dementia. It is developing a novel drug to treat the condition and other age-related neurodegenerative diseases. The lead candidate drug Xanamem™, blocks the development of cortisol which appears to contribute to cognitive impairment and amyloid plaques. The Company is currently undertaking a second Phase I multiple ascending dose trial in healthy volunteers with results in mid-2015 and plans to undertake a Phase II study in 2016.